Introduction {#Sec1}
============

Organized screening programs for breast cancer have been estimated to reduce breast cancer mortality by about 23 % among those invited. On the other hand, however, it has also been shown to increase the risk of cumulative false positive results by about 20 % \[[@CR1]\]. These estimates describe mainly screening programs that invite women aged 50--69 or 50--74 years. There is no clear evidence on effectiveness of systematic clinical breast examination without mammography or of breast self-examination \[[@CR1], [@CR2]\]. In addition to sole mammography as the screening test, some programs or trials have performed clinical or physical examination \[[@CR3]\]. Clinical examination means systematic palpation by specifically trained staff \[[@CR3]\]. However, the clinical examination in Finland is done by collecting self-reported information on symptoms during the screening examination as well as inspection of breasts by the radiographer.

Self-reported symptoms as well as radiographer reports on observations have been a part of the mammography screening program in Finland, since the program started in the late 1980s \[[@CR3], [@CR4]\]. Cross-sectional studies have indicated that symptoms have important consequences on the performance of screening \[[@CR5]--[@CR7]\]. There is a risk that harms of screening may increase, as information on symptoms launch further assessments not dealing with breast cancer. The findings of the physical examination may also relate to long-term patterns over several screening rounds.

The main purpose of this study was to estimate the cumulative probability of false positive mammography tests and true positives in women's visits with symptoms, compared with those visits with no reported symptoms at mammography screening in the Finnish programme in women aged 50--69 years. In addition, we estimated the risk of false positive test and true positive with accumulated same symptom or any symptoms in the screening history.

Materials and methods {#Sec2}
=====================

Study design, setting, and data source {#Sec3}
--------------------------------------

The current study is a register-based cohort study, which utilizes the screening visit history of women who attended the mammography screening program in Finland. The program invited women aged 50--69 years every second year for mammography screening in special organized clinics. Information on breast cancer screening has been registered at the Mass Screening Registry which is part of the Finnish Cancer Registry. The women were asked about breast symptoms at the visit. Any symptoms (lump, retraction, secretion, mole, and scar) women had during the past 2 months were recorded on the mammography form ([http://www.cancer.fi/\@Bin/44068785/Mammography+form_2006.pdf](http://www.cancer.fi/%40Bin/44068785/Mammography%2bform_2006.pdf)). The mammography screening examination was two-view for both breasts. The detailed mammography screening process has been described earlier \[[@CR5]\]. The registration coverage increased with time, from 51.2 % in 1992 to 90 % in 1998 and virtually 100 % in 2005 and afterwards \[[@CR4]\].

The current study population included 413,611 women who were invited for the first time at age 50--51 years in 1992--2004 and were followed up until 2012. Altogether, 2,627,256 invitations were identified during the period 1992--2012, out of which 2,283,706 (87 %) visits were made with an average of 5.5 visits per woman. Records with missing data on symptoms were excluded from the analysis (Table [1](#Tab1){ref-type="table"}). The maximum number of visits per woman was 10, and visits exceeding 10 (145 visits) due to migration within the country were excluded from the current analysis.

Definition of variables {#Sec4}
-----------------------

Test positives are those with primary mammography positive---they are recalled for further assessment (often more mammograms, ultrasound, and needle biopsy) at the screening clinic, if the mammogram indicated any abnormality. The assessment part is called an episode and those with a positive episode are referred to hospital for diagnostics/treatment. Test positives may be episode negative (no referral) or episode positives (referred) and those who are then diagnosed with cancer are true positives at all stages. False positive test are those with negative episode or with a positive episode but no cancer diagnosis at hospital. False positive mammography tests were further classified as at least one or first false positives depending on the screening history: 'at least one' if a woman was detected as false positive at any given screening visit irrespective of earlier visit findings and 'first' if a woman was detected as false positive at any given screening visit given that mammography in all previous visits was negative. False positive referrals are those with episode positive but no cancer diagnosis in hospital. The average number of visits per woman was defined as the total number of visits made at ages 50--69 years divided by the number of women screened during that period of age. Number of invitations per woman was counted as the number of subsequent invitations a woman received after the first invitation at age 50--51 years.

Women with symptoms reported either by the woman herself or by the radiographer were considered as symptomatic. Symptoms history variable for either lump or retraction or secretion, was created and defined as symptoms reported ever before or at the index visit. Here, index visit means the visit that resulted in a positive test result (either false positive test or true positive test). The possibility of reporting more than one symptom at a single screening visit was also considered. For that, combinations of two symptoms at a time were made as 'none,' 'either' and 'both.' Separate variables for each symptom reported once or more than once in the screening history were created and coded as '1 time' and 'more than 1 time.' A separate variable on the absolute number of visits (1--10) per woman was created to compare the probability of false positive test by screening visits, overall versus those with symptoms history.

Statistical analysis {#Sec5}
--------------------

Lump, retraction, and secretion, the most clinically relevant symptoms, were used for analysis. Let *i* be the index subjects *i* = 1,..., *n* and *j* be the index visits of *i*th subject *j* = 1,..., *J*~*i*~. We note by *P*(*Y*~*ij*~ = 1; *X*~*ij*~) the probability of a false positive test for subject *i* at the *j*th screen given covariates *X*~*ij*~. The cumulative risk of first outcome event after *k* rounds of screening is $\documentclass[12pt]{minimal}
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Results {#Sec6}
=======

In 56,805 (2.5 %) visits at least one symptom was reported during the study period in 1992--2012 with a maximum follow-up of 21 years. A lump was reported in 26,145 (1.22 %) visits, retraction in 26,653 (1.59 %) visits, and secretion was reported in 5325 (0.24 %) visits (Fig. [1](#Fig1){ref-type="fig"}). There were combined symptoms, as well, with both lump and retraction at 557 visits, lump and secretion at 572 visits, and retraction and secretion at 207 visits. Overall, 48,873 visits (2.1 %) out of total visits had false positive tests. Of these, 44,541 false positive tests were confirmed one time and 4332 false positive test were confirmed more than one time in women screening history. The false positive test percentage at a given visit was 7.2 % (4063 visits) in women with symptoms compared to 2.0 % (44,810 visits) in women with no symptoms. Similarly, the true positive (breast carcinoma) percentage was 2.2 % (1230 visits) in women who reported symptoms compared to 0.4 % (9718 visits) in women with no symptoms (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of mammography screening program by symptom status

The percentage of women who reported a lump or secretion was higher in younger age groups compared to the older age groups (lump = 1.71 vs. 0.78 %; secretion = 0.32 vs. 0.04 % at 1st and 10th visit, respectively) (Table [1](#Tab1){ref-type="table"}). The false positive proportion among women who reported any symptoms was significantly higher at every visit (order, 1--10) compared to those who did not report any symptoms, overall 7.2 vs. 1.5 %, respectively. False positive test probability based on the absolute number of woman's visits showed similar difference in women with symptom history compared to women with no history of symptoms (Fig. [2](#Fig2){ref-type="fig"}). However, false positive test probability was lower in women who had less (absolute) number of visits compared to those who had completed all possible (ten visits) screening visits. Similarly, the false positive referral and true positive proportions were higher among women who reported symptoms versus no reported symptoms, 2.8 vs. 0.6 % and 2.2 vs. 0.4 %, respectively. Table 1Number and percentage of symptoms, false positive test and true positives (of symptoms) by number of visitsSymptomsNumber of visitNumber of visits with symptoms (%)All visitsMissing visitsFalse positive testFalse positive referralTrue positivesCurrent symptoms (%)No current symptoms (%)Current symptoms (%)No current symptoms (%)Current symptoms (%)No current symptoms (%)Lump16034 (1.71)353,34842,672922 (15.9)13,756 (3.98)69 (1.14)1196 (0.34)238 (3.94)1438 (0.41)24374 (1.26)347,91537,845569 (13.5)6890 (2.01)32 (0.73)444 (0.13)146 (3.34)1110 (0.32)33814 (1.09)349,66924,440419 (11.4)6057 (1.76)33 (0.87)400 (0.12)127 (3.33)1327 (0.38)43640 (1.08)337,34020,857376 (10.7)5244 (1.58)17 (0.47)317 (0.09)132 (3.63)1390 (0.42)53469 (1.10)314,84611,177378 (11.3)4564 (1.47)27 (0.78)301 (0.10)118 (3.40)1536 (0.49)62442 (1.11)220,4143844270 (11.5)3047 (1.41)20 (0.82)231 (0.11)97 (3.97)1233 (0.57)71522 (1.11)136,5402105126 (8.61)1868 (1.39)11 (0.72)138 (0.10)59 (3.88)825 (0.61)8708 (1.07)66,31048062 (9.13)865 (1.33)3 (0.42)64 (0.10)29 (4.10)430 (0.66)9122 (1.08)11,3173614 (12.2)181 (1.63)017 (0.15)7 (5.74)79 (0.71)1020 (0.78)254904 (21.1)55 (2.19)06 (0.24)1 (5.0)22 (0.87)Overall26,145 (1.22)2,140,248143,4583140 (12.5)42,527 (1.73)212 (0.81)3114 (0.15)954 (3.65)9390 (0.44)Retraction11446 (1.00)145,113250,90781 (5.74)5529 (3.87)5 (0.35)395 (0.27)36 (2.49)776 (0.54)22364 (1.13)209,617176,14369 (2.95)4271 (2.07)7 (0.30)247 (0.12)27 (1.14)790 (0.38)33519 (1.29)273,512100,599109 (3.13)4772 (1.78)12 (0.34)301 (0.11)31 (0.88)1169 (0.43)44597 (1.49)307,51250,685110 (2.42)4894 (1.62)8 (0.17)291 (0.10)43 (0.94)1339 (0.44)55383 (1.76)306,05919,964109 (2.05)4693 (1.57)3 (0.06)313 (0.10)67 (1.24)1537 (0.51)64542 (2.06)220,381387796 (2.14)3220 (1.50)5 (0.11)246 (0.11)54 (1.19)1276 (0.59)73005 (2.20)136,540210556 (1.88)1938 (1.46)2 (0.07)147 (0.11)31 (1.03)853 (0.64)81502 (2.27)66,31048030 (2.01)897 (1.39)4 (0.27)63 (0.10)12 (0.80)447 (0.69)9244 (2.16)11,317366 (2.48)189 (1.72)017 (0.15)2 (0.82)84 (0.76)1051 (2.0)254902 (3.92)57 (2.30)06 (0.24)023 (0.92)Overall26,653 (1.59)1,678,910604,796668 (2.54)30,460 (1.85)46 (0.17)2026 (0.12)303 (1.14)8294 (0.50)Secretion11142 (0.32)358,58337,437126 (11.1)14,557 (4.09)20 (1.75)1235 (0.35)6 (0.53)1712 (0.48)21004 (0.28)360,09325,66771 (7.13)7557 (2.11)13 (1.29)483 (0.13)8 (0.80)1302 (0.36)3909 (0.25)360,91013,20168 (7.55)6598 (1.84)10 (1.10)451 (0.13)8 (0.88)1506 (0.42)4807 (0.23)350,660753763 (7.89)5717 (1.64)17 (2.11)337 (0.10)9 (1.12)1588 (0.45)5667 (0.21)322,477354654 (8.24)4993 (1.56)13 (1.95)322 (0.10)12 (1.80)1688 (0.52)6481 (0.22)220,398386025 (5.26)3292 (1.51)5 (1.04)246 (0.11)6 (1.25)1324 (0.60)7209 (0.15)136,52221239 (4.45)1985 (1.47)4 (1.91)145 (0.11)2 (0.96)881 (0.65)892 (0.14)66,2974935 (5.62)922 (1.40)1 (1.09)66 (0.10)3 (3.26)456 (0.69)913 (0.11)11,312412 (15.4)193 (1.72)2 (15.4)15 (0.13)086 (0.76)101 (0.04)25481059 (2.34)06 (0.24)023 (0.90)Overall5325 (0.24)2,189,80093,906423 (8.03)45,873 (2.11)85 (1.60)3306 (0.15)54 (1.01)10,566 (0.48)Fig. 2False positive (FP) test probability; overall (**i**) and any symptoms (**ii**), by attended number of screening visits of women

Table [2](#Tab2){ref-type="table"} shows the at least one cumulative false positive test and true positive probability after 10 visits. The cumulative probabilities of at least one false positive test, false positive referral, and true positive were 18.2, 1.5, and 5.7 %, respectively, after 10 visits. The cumulative probability of first false positive test was 15.9 % (not shown in Table).Table 2Cumulative probability of at least one false positive (FP) test, FP referral, and true positive after 10 screening visitsScreen numberFP test probabilityCumulative FP test probabilityFP referral probabilityCumulative FP referral probabilityTrue-positive probabilityCumulative probability of true-positive10.04070.04070.00340.00340.00470.004720.02160.06140.00140.00480.00370.008430.01870.07900.00130.00610.00420.012540.01670.09440.00100.00710.00450.017050.01590.10890.00100.00810.00530.022260.01540.12260.00110.00920.00600.028170.01490.13570.00110.01030.00650.034480.01410.14790.00100.01130.00690.041190.01740.16270.00150.01280.00760.0483100.0224**0.1822**0.0024**0.0151**0.0090**0.0569**Bold numbers indicate the final cumulative number

The cumulative probability of having at least one false positive test was significantly higher in those who had a history of lump compared to those with no history of lump, 45.2 vs. 17.2 % estimated for 10 visits. Cumulative probability of at least one false positive referral and true positive in women who reported any symptoms in screening history were 3.8 and 12.6 %, respectively, compared to 1.4 and 5.3 %, in women with no history of any symptom. (Table [3](#Tab3){ref-type="table"}) There was some increase in the probability of false positive test before the visit with a lump compared to visits with no lump, though true positive probability did not differ (see supplementary table, S1). Women who reported lump or secretion more than one time had higher cumulative probability of at least one false positive test than women who reported lump or secretion once in screening history, 47.8 vs. 44.0 % for lump and 39.8 vs. 33.4 % for secretion, respectively. However, cumulative probability of true positive was lower in women who reported symptoms more than one time compared to one time in screening history.Table 3Cumulative probability of at least one false positive (FP) test, FP referral, and true positive in women with a history of symptomsSymptoms historyCumulative probability of false positive testCumulative probability of false positive referralCumulative probability of true positiveLump Yes0.45160.03320.1630  1 time 0.44010.03570.2002  \>1 time0.47800.02680.0650 No0.17210.01460.0531Retraction Yes0.24640.02610.0903  1 time0.26620.04290.1868  \>1 time0.23420.01590.0368 No0.18070.02040.0567Secretion Yes0.34770.07890.0638  1 time0.33390.06770.0691  \>1 time0.39810.12390.0489 No0.18110.01460.0569Any symptom Yes0.38430.03770.1262  1 time0.39380.04220.1730  \>1 time0.36940.03150.0533 No0.16990.01380.0530

The cumulative false positive probability in women who reported 'lump and retraction' was higher, 56.5 % (95 % CI 47.4--66.3) compared to those who did not report either symptom, 17.1 % (95 % CI 16.6--17.7) (Fig. [3](#Fig3){ref-type="fig"}). For Women who reported 'lump and secretion, the cumulative false positive test probability was 54.8 % (95 % CI 45.3--69.6).Fig. 3Cumulative probability of at least one false positive (FP) test among women reported symptoms at screen

Discussion {#Sec7}
==========

Our study found significantly higher cumulative false positive test and true positive probability among those who reported symptoms at screen compared to those who did not report any symptoms. The cumulative risk of false positive test (after 10 rounds) with any symptom was 38 % and that without was 17 %. Lump was associated with the highest cumulative false positive risk of 45 %, retraction 25 %, and secretion 35 %.

The overall cumulative probability of at least one false positive test was 18 % after 10 screening visits at age 50--69 years and the false positive test probability was 3.6 % at the first visit at age 50--51 years. Our results are consistent or somewhat lower with that of previous studies from other European countries \[[@CR10]--[@CR17]\]. A study from Norway reported a higher cumulative false positive risk (23 %) than the current study \[[@CR10]\]. Another study estimated a 21 % cumulative false positive probability projected after 10 screening visits, based on the results of three consecutive screening visits performed in four counties \[[@CR11]\]. A retrospective cohort study from Spain projected the cumulative false positive risk to be 20.4 % after 10 screening visits \[[@CR12]\]. Cumulative false positive probability from a randomized trial in the UK (2010) was 20.5 % over seven screening rounds \[[@CR16]\]. A Danish study \[[@CR14]\] made the prediction, based on 3--5 observed screening rounds, of cumulative false positive test probability slightly lower than that of our study. However, the false positive test probability at first screen was higher (5.7 %) in Copenhagen than that of the current study. In the Netherlands, Otten et al. (2013) found lower cumulative false positive risk after 13 consecutive screening examinations than that of our study, but they expected higher estimates after digital mammography was introduced in 2003 \[[@CR18], [@CR19]\]. Nonetheless, there were some variations between countries in the methodology and health service system, such as age at first invitation \[[@CR10], [@CR14], [@CR18]\], projected estimates based on few observed rounds \[[@CR11], [@CR18]\], and lower recall proportion of \<1 % at subsequent screens \[[@CR18], [@CR20]\] compared to 2.2 % in our study and \<3 % in European guidelines \[[@CR21]\], while estimating the false positive risk.

Studies conducted in the USA have reported much higher risk of cumulative false positive tests than that of the current study \[[@CR8], [@CR22]--[@CR25]\]. In the US, Breast Cancer Surveillance Consortium (BCSC) data from all women (*n* = 88,455) first screened at age 50-69 years between 1996 and 2010 estimated the cumulative false positive risk to be 41.9 % after eight screens annually or biennially \[[@CR24]\]. The reason for lower estimates in our study may be due to different program organizations in Finland than in USA as well as variation in age at first screening, definitions of recall, recording and coding of screening data, screening interval, etc. \[[@CR26]\]. Also, the European quality standards \[[@CR21]\] are adequately met by the Finnish screening program.

Together with the cumulative probability of 'at least one' false positive, this study also estimated the cumulative 'first' false positive test and true positive probability. The cumulative first false positive probability was 16 % as we considered only the first false positive mammography result, excluding later false positive findings of the same woman. Hence, the estimate is lower than the 'at least one' false positive estimate. Also, the lower probability of false positive in our study may be due to the exclusion of the first visits made at later age, hence removing contamination of newcomers at later visits with prevalent screens. Our study estimated the cumulative true positive probability to be 6 % after 10 screening visits. A study in the Netherlands estimated similar cumulative cancer detection risk after 13 consecutive screening examinations \[[@CR18]\]. We are not aware of other studies on cumulative true positive estimates after 10 screening visits.

No prior studies have estimated the cumulative probability based on reported symptoms with a complete follow-up information. Women who reported having symptoms, especially lump and secretion at screening visit, current or at any previous visit, were significantly more likely to have a false positive test and true positive result than women with no symptoms reported. The cumulative false positive probability in women with a history of lump was 45 % compared to 17 % with no lump. When considering the full visit history of women with lump, before and after visit with lump, the higher probability of false positive test before the visit with a lump indicates that there was a possibility that some unspecific changes in the mammograms had been seen even several years before the visit when a lump was reported. On the other hand, after reporting the first symptom there was no increase in the probability of false positive test and true positive results in the later visits. This means that woman was treated and no cancer was detected in later visits. Women were more likely to be true positive if they reported symptoms at screen; cumulative true positive probability of 16 % was compared to 6.5 % with no reported lump. Similarly, women who reported both 'lump and retraction' in the same visit had cumulative false positive test probability of 56.5 % (95 % CI 47.4--66.3) compared to 17.1 % (95 % CI 16.6--18.3) without symptoms. Similar results were found in women with other possible combination of symptoms. Taking into account the information on breast symptoms, there is a concern for the radiologist whether or not to recall the symptomatic women. Also, variation in the false positive probability by symptom status, number of times symptom was reported, shows that not all symptoms are equally sensitive. At the same time, the findings also showed benefits of evaluating symptoms information on the performance (more cancers detected) of mammography screening program.

One of the limitations of this study is the missing information on some important risk factors such as hormone use, breast density, and family history of breast cancer, while estimating the cumulative false positive and true positive probability in relation to symptoms. The missing information (1.2 % of total visits) on symptoms was due to incomplete reporting by some centers in the early years of the program. Women recalled but not referred to hospital and women referred but with no cancer in histological confirmation who may have had a cancer before the next screening visit (interval cancer), were not taken into account in this study. Other performance measures of screening program, including interval cancers and mortality as stated by Otten et al. \[[@CR18]\] and Tornberg et al. \[[@CR27]\], in relation to breast symptoms need to be evaluated thoroughly.

The current study is based on a large nationwide screening cohort with complete follow-up of the women up to maximum 10 visits (21 years). The high participation rate (\>85 %) in the screening program and few opportunistic screening means false positive probability estimates over the 10 screens equals the lifetime risk of false positive test in Finland, which is similar to that reported by a Danish study \[[@CR14]\]. The radiologists learning of the previous mammography results and the small difference between 'at least one' and 'first' cumulative probability estimates form the basis to conclude independence between false positive risks at subsequent screen.

In conclusion, the current study showed that information about breast symptoms, especially lump, cause harms in terms of extra false positive findings. The risk varies substantially, depending on symptom types and characteristics. At the same time, more cancers were detected in symptomatic women suggesting benefits of evaluating symptoms information in the program. Information on breast symptoms influences the balance of absolute benefits and harms of screening for the individual woman, and should be considered carefully in breast cancer screening programs.
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